Latest Security News

Macarthur Minerals has updated its rights issue prospectus, introducing a cap on the underwriter's shareholding and revising key offer terms. These changes aim to balance funding needs with shareholder control and regulatory compliance.

NeuroScientific Biopharmaceuticals has completed its acquisition of StemSmart technology, reporting promising clinical results in Crohn’s disease and GVHD, alongside a $3.5 million capital raise to fuel next-stage development.

Elsight Limited has raised A$60 million through a strongly supported placement, marking a milestone with consecutive record revenues and cash flow breakeven. The company is poised to capitalize on surging defence budgets and expanding drone markets with a robust pipeline of opportunities.

Elsight Limited reports record-breaking revenue growth in Q2 and H1 2025, driven by major defence contracts and expanding market opportunities, positioning the company for profitability later this year.

Elsight Limited reports a record 340% revenue surge to US$4.8 million in the first half of 2025, backed by a robust US$11.45 million contract backlog and a strategic A$60 million capital raise to fuel expansion.

GenusPlus Group has won an additional $60 million contract extension from Western Power, reinforcing its role in expanding WA’s renewable energy transmission network.

Peregrine Gold has announced a major discovery of a high-grade Channel Iron Deposit spanning over 7.7km near established BHP iron ore operations in Western Australia, signaling a promising new chapter for the Newman Gold Project.

Woodside Energy reported a 2% rise in quarterly production and lowered unit costs, while the Louisiana LNG Project’s final investment decision and a major Stonepeak partnership unlock significant future value.

AdAlta Limited has prioritized two promising CAR-T cellular immunotherapy products for licensing agreements and successfully raised $1.3 million to support its strategic expansion. The company’s focused capital management and pipeline refinement signal a pivotal phase in its ‘East to West’ strategy.

Tetratherix Limited has marked a pivotal quarter with a $25 million ASX listing, an exclusive licensing agreement with Bio Optix for ophthalmic devices, and progress on FDA regulatory submissions for its prostate spacer product.

Alligator Energy reports a 10% increase in indicated uranium resources at its Samphire Project, secures a $17.25 million capital raise, and announces a CEO transition as it advances key uranium exploration and development milestones.

Argenica Therapeutics has dosed the final patient in its Phase 2 trial for ARG-007 in acute ischaemic stroke, with topline results expected in Q3 2025. Meanwhile, the FDA has placed a clinical hold on its US trial application, introducing uncertainty for US development.